To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 3
This profile is validated by 3 label.

Company

Applied Research using OMIC Sciences

Applied Research using OMIC Sciences_logo
46
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

AROMICS is a development-stage biotechnology company focused on development of novel therapies and molecular diagnostic methods for the management and treatment of cancer and infectious diseases.

Barcelona, Catalonia, Spain

Send a message

English

Applied Research using OMIC Sciences

English

AROMICS is  a development-stage biotech company based in Barcelona and focused on development of novel therapies for the treatment of important human disease like cancer. Over last years the company has been focused on the development of small molecules targeting RNA. A first lead is advancing into clinical trials in a first indication, malignant mesothelioma, a rare and incurable disease linked to asbestos exposure.

  • 1

    Followers

Our latest news

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

InvestEU Portal
Being an integral part of the InvestEU programme of the European Commission, the InvestEU Portal brings together investors and project promoters by providing a list of pre-checked quality projects in all economic sectors across all EU Member States. Therefore, qualified investors have the opportunity to easily screen various projects before deciding on which ones to invest in.
74 Entities
InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
454 Entities
Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not receive funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1482 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2672 Members
Access2EIC
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
2141 Members
ESIL - Early Stage Investing Launchpad
A pan-european community to develop awareness-raising and capacity-building for business angels and other early-stage investors.
464 Members

Our history

Start in 02/09/2005

  • 02/09/2005

    Four entrerprenours created AROMICS to try to integrate OMIC sciences in drug development process.

  • 2011-2013

    Join agreement with Acceleration Biopharmaceuticals for AB200 development for viral coinfection

  • 2012-2015

    R&D collaboration agreement with Naxospharma srl for the development of novel NAX anticancer agents

  • 2016

    European Patent granted and entrance on Spanish country of NAX35 anticancer agent. License agreement

  • 2021-2022

    Completing preclinical package first lead i mesothelioma. Advancing into clinicla trials.

to be continued ...